Malignant and Noninvasive Skin Tumours in Renal Transplant Recipients

Background. Transplant recipients require immunosuppression to prevent graft rejection. This conveys an increased risk of malignancy, particularly skin tumours. There is a need for up-to-date data for the South of England. Method. Pathology records were reviewed for 709 kidney transplant recipien...

Full description

Saved in:
Bibliographic Details
Main Authors: Christopher D. Roche, Joelle S. Dobson, Sion K. Williams, Mara Quante, Joyce Popoola, Jade W. M. Chow
Format: Article
Language:English
Published: Wiley 2014-01-01
Series:Dermatology Research and Practice
Online Access:http://dx.doi.org/10.1155/2014/409058
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832550389885435904
author Christopher D. Roche
Joelle S. Dobson
Sion K. Williams
Mara Quante
Joyce Popoola
Jade W. M. Chow
author_facet Christopher D. Roche
Joelle S. Dobson
Sion K. Williams
Mara Quante
Joyce Popoola
Jade W. M. Chow
author_sort Christopher D. Roche
collection DOAJ
description Background. Transplant recipients require immunosuppression to prevent graft rejection. This conveys an increased risk of malignancy, particularly skin tumours. There is a need for up-to-date data for the South of England. Method. Pathology records were reviewed for 709 kidney transplant recipients on immunosuppression at our hospital from 1995 to 2008. Skin tumours were recorded/analysed. Results. Mean age at transplant was 46 years. Mean length of follow-up was 7.2 years and total follow-up was 4926 person-years. 53 (7.5%) patients (39/458 (8.5%) males and 14/251 (5.6%) females) developed ≥1 skin malignancy. Cumulative incidences of 4.0%, 7.5%, and 12.2% were observed for those with <5, <10, and ≥10 years follow-up, respectively. The rate was 45 tumours per 1000 person-years at risk. Additionally, 21 patients (3.0%) only had noninvasive tumours. 221 malignant skin tumours were found: 50.2% were SCCs, 47.1% BCCs, and 2.7% malignant melanomas. Mean years to first tumour were 5.8. Mean number of tumours per patient was 4, with mean interval of 12 months. Conclusions. Despite changes in transplantation practice during the time since the last data were published in this region, these findings are similar to previous studies. This adds to the evidence allowing clinicians to inform patients in this region of their risk.
format Article
id doaj-art-f6c6184de1e544539bb8041635a35300
institution Kabale University
issn 1687-6105
1687-6113
language English
publishDate 2014-01-01
publisher Wiley
record_format Article
series Dermatology Research and Practice
spelling doaj-art-f6c6184de1e544539bb8041635a353002025-02-03T06:07:01ZengWileyDermatology Research and Practice1687-61051687-61132014-01-01201410.1155/2014/409058409058Malignant and Noninvasive Skin Tumours in Renal Transplant RecipientsChristopher D. Roche0Joelle S. Dobson1Sion K. Williams2Mara Quante3Joyce Popoola4Jade W. M. Chow5St George’s, University of London, Cranmer Terrace, London SW17 0RE, UKSt George’s, University of London, Cranmer Terrace, London SW17 0RE, UKThe National Hospital for Neurology, 23 Queen Square, London WC1N 3BG, UKDepartment of Histopathology, Royal Sussex County Hospital, Eastern Road, Brighton BN2 5BE, UKDepartment of Renal Medicine and Transplantation, St George’s Healthcare NHS Trust, Blackshaw Road, London SW17 0QT, UKSt George’s, University of London, Cranmer Terrace, London SW17 0RE, UKBackground. Transplant recipients require immunosuppression to prevent graft rejection. This conveys an increased risk of malignancy, particularly skin tumours. There is a need for up-to-date data for the South of England. Method. Pathology records were reviewed for 709 kidney transplant recipients on immunosuppression at our hospital from 1995 to 2008. Skin tumours were recorded/analysed. Results. Mean age at transplant was 46 years. Mean length of follow-up was 7.2 years and total follow-up was 4926 person-years. 53 (7.5%) patients (39/458 (8.5%) males and 14/251 (5.6%) females) developed ≥1 skin malignancy. Cumulative incidences of 4.0%, 7.5%, and 12.2% were observed for those with <5, <10, and ≥10 years follow-up, respectively. The rate was 45 tumours per 1000 person-years at risk. Additionally, 21 patients (3.0%) only had noninvasive tumours. 221 malignant skin tumours were found: 50.2% were SCCs, 47.1% BCCs, and 2.7% malignant melanomas. Mean years to first tumour were 5.8. Mean number of tumours per patient was 4, with mean interval of 12 months. Conclusions. Despite changes in transplantation practice during the time since the last data were published in this region, these findings are similar to previous studies. This adds to the evidence allowing clinicians to inform patients in this region of their risk.http://dx.doi.org/10.1155/2014/409058
spellingShingle Christopher D. Roche
Joelle S. Dobson
Sion K. Williams
Mara Quante
Joyce Popoola
Jade W. M. Chow
Malignant and Noninvasive Skin Tumours in Renal Transplant Recipients
Dermatology Research and Practice
title Malignant and Noninvasive Skin Tumours in Renal Transplant Recipients
title_full Malignant and Noninvasive Skin Tumours in Renal Transplant Recipients
title_fullStr Malignant and Noninvasive Skin Tumours in Renal Transplant Recipients
title_full_unstemmed Malignant and Noninvasive Skin Tumours in Renal Transplant Recipients
title_short Malignant and Noninvasive Skin Tumours in Renal Transplant Recipients
title_sort malignant and noninvasive skin tumours in renal transplant recipients
url http://dx.doi.org/10.1155/2014/409058
work_keys_str_mv AT christopherdroche malignantandnoninvasiveskintumoursinrenaltransplantrecipients
AT joellesdobson malignantandnoninvasiveskintumoursinrenaltransplantrecipients
AT sionkwilliams malignantandnoninvasiveskintumoursinrenaltransplantrecipients
AT maraquante malignantandnoninvasiveskintumoursinrenaltransplantrecipients
AT joycepopoola malignantandnoninvasiveskintumoursinrenaltransplantrecipients
AT jadewmchow malignantandnoninvasiveskintumoursinrenaltransplantrecipients